LeMaitre Vascular, Inc. (LMAT) Market Cap & Valuation Ratios
LeMaitre Vascular, Inc. (LMAT) has a market cap of $1.9B, a trailing P/E of 29.6 and a price-to-sales ratio of 7.4, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LMATLeMaitre Vascular, Inc.Follow LMAT — free
—
Price chart with a free account
- Market cap
- 1.9B
- P/E TTM
- 29.6
- Dividend yield
- 1.1%
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Peers
medical instruments & supplies · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LMAT | 1.9 | 29.6 | 6.6 | 19.6 | 3.8% | +12% | 29% | 11% |
| ICUI | 4.2 | — | 2.4 | 18.7 | 3.7% | -9% | 3% | 1% |
| NVST | 3.8 | 40.7 | 1.4 | 10.5 | 6.5% | +12% | 10% | 3% |
| PLSE | 3.8 | — | — | — | -1.6% | — | — | — |
| WRBY | 3.2 | — | 3.2 | 52.9 | 0.7% | +11% | 0.2% | 1% |
| ATRC | 3.0 | — | 5.1 | 85.7 | 1.8% | +14% | 2% | 3% |
| XRAY | 1.9 | — | 1.1 | 99.1 | 7.6% | -0.8% | -9% | -8% |
| KMTS | 1.7 | — | 14.9 | — | -7.2% | +61% | -134% | -114% |
| AZTA | 1.6 | — | 2.1 | — | 0.6% | +5% | -29% | -13% |
| DRTS | 1.2 | — | — | — | -1.3% | — | — | -93% |
| STAA | 1.1 | — | 2.8 | 42.8 | -0.6% | +51% | 4% | 6% |
| Median of these 10 | 40.7 | 2.6 | 47.9 | 0.6% | +11% | 1% | 1% |
P/E 29.6 vs. a peer median of 40.7; EV/Sales 6.6 vs. 2.6. LMAT's own P/E sits at the 5th percentile of its history.
Growth vs. price
each dot a company · hover or tap for valuesLeMaitre Vascular, Inc. — questions
- What is LeMaitre Vascular, Inc.'s market cap?
- $1.9B.
- What is LeMaitre Vascular, Inc.'s P/E ratio?
- 29.6 on trailing twelve-month earnings to 2026-06-30.
- What is LeMaitre Vascular, Inc.'s price-to-sales ratio?
- 7.4.
Every figure on this page comes from LeMaitre Vascular, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.